# PNMA2

## Overview
PNMA2, or Paraneoplastic Ma Antigen 2, is a gene that encodes a protein belonging to the PNMA family, which is primarily expressed in neuronal tissues, particularly within the brain. The PNMA2 protein is implicated in synaptic signaling and is thought to play a role in neuroprotection and neurodegenerative processes, although its precise molecular functions in healthy cells remain to be fully elucidated (Schüller2005The; Beutgen2020Autoantigens). The gene's expression is notably restricted to immune-privileged sites, such as the brain and testis, highlighting its potential significance in maintaining normal neuronal function and possibly in protecting against neurodegeneration (Schüller2005The; Leja2009Novel). Additionally, PNMA2 is involved in immune responses, particularly in the context of paraneoplastic syndromes, where its expression in tumor cells can elicit an autoimmune response (Leja2009Novel). The protein's interaction with MOAP1, a modulator of apoptosis, further suggests its involvement in neuron-related diseases (Su2022Revealing).

## Function
PNMA2, or Paraneoplastic Ma Antigen 2, is a gene that encodes a protein primarily expressed in neuronal tissues, particularly in the brain. In healthy human cells, PNMA2 is involved in cellular processes related to the immune response and is associated with neuronal function (Schüller2005The; Leja2009Novel). The protein is part of the PNMA family, which includes several members known for their expression in immune-privileged sites like the brain and testis (Schüller2005The).

PNMA2 proteins are implicated in synaptic signaling, suggesting a role in neuroprotection and neurodegenerative processes. Although the specific molecular activities of PNMA2 in healthy cells are not fully detailed, its expression pattern indicates a potential involvement in maintaining normal neuronal function and possibly in protecting against neurodegeneration (Beutgen2020Autoantigens). The presence of PNMA2 in neuronal tissues and its restricted expression pattern in healthy cells highlight its significance in the central nervous system (Leja2009Novel).

The role of PNMA2 in immune response is also notable, as its expression in tumor cells can trigger an autoimmune response, leading to the production of autoantibodies and specific cytotoxic T cells (Leja2009Novel). However, the exact function of PNMA2 in healthy human cells remains an area for further research.

## Clinical Significance
PNMA2 (Paraneoplastic Ma antigen 2) is implicated in several neurological and systemic conditions due to its role as an antineuronal antibody. It is identified as a marker for neurological paraneoplastic syndromes, which are disorders triggered by an immune response to cancer. PNMA2 is particularly significant in the early detection of small bowel neuroendocrine neoplasms (SB-NENs), where it can identify nearly 50% of cases at the primary stage and is associated with disease progression and recurrence-free survival (HerreraMartínez2019Neuroendocrine).

In the context of type 2 diabetes (T2D) and neurological diseases, PNMA2 has been identified as a differentially expressed gene, suggesting potential molecular links between T2D and neurological conditions such as Alzheimer's and Parkinson's diseases. The study highlights immune system and signaling pathways as common pathways between these conditions (Rahman2019Bioinformatics).

PNMA2 also interacts with MOAP1, a protein involved in apoptosis. It functionally antagonizes the pro-apoptotic effects of MOAP1 and PNMA1, indicating a role in modulating apoptosis in neuron-related diseases (Su2022Revealing). This interaction suggests that alterations in PNMA2 expression or function could contribute to neurodegenerative processes.


## References


[1. (HerreraMartínez2019Neuroendocrine) Aura D Herrera-Martínez, Leo J Hofland, María A Gálvez Moreno, Justo P Castaño, Wouter W de Herder, and Richard A Feelders. Neuroendocrine neoplasms: current and potential diagnostic, predictive and prognostic markers. Endocrine-Related Cancer, 26(3):R157–R179, March 2019. URL: http://dx.doi.org/10.1530/erc-18-0354, doi:10.1530/erc-18-0354. This article has 36 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1530/erc-18-0354)

[2. (Su2022Revealing) Yanfang Su, Weixia Wang, and Xianfang Meng. Revealing the roles of moap1 in diseases: a review. Cells, 11(5):889, March 2022. URL: http://dx.doi.org/10.3390/cells11050889, doi:10.3390/cells11050889. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cells11050889)

[3. (Rahman2019Bioinformatics) Md Habibur Rahman, Silong Peng, Xiyuan Hu, Chen Chen, Shahadat Uddin, Julian M. W. Quinn, and Mohammad Ali Moni. Bioinformatics methodologies to identify interactions between type 2 diabetes and neurological comorbidities. IEEE Access, 7:183948–183970, 2019. URL: http://dx.doi.org/10.1109/ACCESS.2019.2960037, doi:10.1109/access.2019.2960037. This article has 32 citations and is from a peer-reviewed journal.](https://doi.org/10.1109/ACCESS.2019.2960037)

[4. (Beutgen2020Autoantigens) Vanessa M Beutgen, Carsten Schmelter, Norbert Pfeiffer, and Franz H Grus. Autoantigens in the trabecular meshwork and glaucoma‐specific alterations in the natural autoantibody repertoire. Clinical &amp; Translational Immunology, January 2020. URL: http://dx.doi.org/10.1002/cti2.1101, doi:10.1002/cti2.1101. This article has 19 citations.](https://doi.org/10.1002/cti2.1101)

[5. (Schüller2005The) Martina Schüller, Dieter Jenne, and Raymond Voltz. The human pnma family: novel neuronal proteins implicated in paraneoplastic neurological disease. Journal of Neuroimmunology, 169(1–2):172–176, December 2005. URL: http://dx.doi.org/10.1016/j.jneuroim.2005.08.019, doi:10.1016/j.jneuroim.2005.08.019. This article has 73 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.jneuroim.2005.08.019)

[6. (Leja2009Novel) Justyna Leja, Ahmed Essaghir, Magnus Essand, Kenneth Wester, Kjell öberg, Thomas H Tötterman, Ricardo Lloyd, George Vasmatzis, Jean-Baptiste Demoulin, and Valeria Giandomenico. Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas. Modern Pathology, 22(2):261–272, February 2009. URL: http://dx.doi.org/10.1038/modpathol.2008.174, doi:10.1038/modpathol.2008.174. This article has 111 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/modpathol.2008.174)